Cancer in Lithuania

IARC estimates 16,368 new cancer cases and 8,037 cancer deaths in Lithuania in 2024; the commonest new cancers are prostate, breast and colorectum. This page is assembled automatically from OnCo's data: 53 trials with a site there, 5 institutions, 4 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

16,368

all cancers

Deaths

8,037

all cancers

Incidence rate

275.9

per 100,000, age-standardised

Mortality rate

113.4

per 100,000, age-standardised

Cumulative risk

27.9%

of a cancer by age 74

Population

2,859,115

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	3,209	130.3	Prostate cancer
Breast	1,716	60.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	1,515	21.4	Colorectal cancer
Trachea, bronchus and lung	1,452	23.2	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Stomach	746	10.8	Gastric & gastro-oesophageal junction cancer
Corpus uteri	702	21.8	Endometrial cancer
Kidney	629	10.3	Renal cell carcinoma
Pancreas	615	8.5	Pancreatic ductal adenocarcinoma
Leukaemia	500	9.0	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Bladder	465	6.3	Bladder & urothelial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,208	17.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	926	11.1	Colorectal cancer
Prostate	558	17.5	Prostate cancer
Pancreas	556	7.5	Pancreatic ductal adenocarcinoma
Breast	550	14.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Stomach	543	7.8	Gastric & gastro-oesophageal junction cancer
Brain, central nervous system	267	5.2	Glioma & glioblastoma
Bladder	263	2.9	Bladder & urothelial cancer
Kidney	260	3.6	Renal cell carcinoma
Liver and intrahepatic bile ducts	253	4.0	Hepatocellular carcinoma

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Lithuania”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

53 trials in OnCo · 15 recruiting overall

53 trials

Trial			Lead sponsor
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation NCT07211958	Phase 3	Recruiting	Syndax Pharmaceuticals	149	2026-09-25
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	251	2026-09-24
AUGMENT-101 NCT04065399	Phase 1/2	Recruiting	Syndax Pharmaceuticals	57	2026-09-16
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B NCT06499285	Phase 3	Recruiting	Takeda	177	2026-08-21
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re NCT06788756	Phase 2/3	Recruiting	Moleculin Biotech, Inc.	28	2026-08-05
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336	Phase 3	Recruiting	AstraZeneca	320	2026-07-29
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC NCT05491525	Phase 2/3	Recruiting	Urovant Sciences GmbH	38	2026-06-15
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. NCT06758830	Phase 2/3	Recruiting	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	1	2026-05-11
PRISM-MEL-301 NCT06112314	Phase 3	Recruiting	Immunocore Ltd	211	2026-02-25
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	142	2025-06-26
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer NCT05797831	Phase 2/3	Recruiting	Kartos Therapeutics, Inc.	83	2024-05-02
Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer NCT05378919	Phase 2	Recruiting	Lithuanian University of Health Sciences	1	2022-05-18
ARANOTE NCT04736199	Phase 3	Completed	Bayer	131	2026-09-29
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P NCT06496178	Phase 3	Active not recruiting	Merus B.V.	194	2026-09-25
LiGeR-HN1 NCT06525220	Phase 3	Active not recruiting	Merus B.V.	202	2026-09-25
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT05673057	Phase 1/2	Completed	Molecular Partners AG	9	2026-09-25
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment- NCT04624204	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	187	2026-09-24
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer ( NCT06077760	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	229	2026-09-18
ELEVATE-TN NCT02475681	Phase 3	Active not recruiting	Acerta Pharma BV	155	2026-08-25
DUO-E / GOG-3041 / ENGOT-EN10 NCT04269200	Phase 3	Active not recruiting	AstraZeneca	201	2026-08-07
KEYNOTE-671 NCT03425643	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	227	2026-07-29
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer NCT04464226	Phase 3	Active not recruiting	Bayer	335	2026-07-07
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) NCT04895722	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	109	2026-07-02
FORTITUDE-101 NCT05052801	Phase 3	Completed	Amgen	300	2026-05-27
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	205	2026-05-15
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer NCT05243550	Phase 3	Active not recruiting	UroGen Pharma Ltd.	65	2026-05-11
IMROZ NCT03319667	Phase 3	Active not recruiting	Sanofi	104	2026-05-04

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Lithuania, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Lithuania is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

5 institutions

Hospital of the Lithuanian University of Health Sciences Kauno Klinikos Klaipėda University Hospital National Cancer Institute, Lithuania Psychosocial Oncology Association (Lithuania)Vilnius University Hospital Santaros Klinikos

4 people

People whose main affiliation in OnCo is an institution or company in Lithuania.

Audrius Šimaitis Renaldas Jurkevičius Tomas Jovaiša Valdas Pečeliūnas

Screening, vaccination and law

Term

Prostate cancer early detection programme in Lithuania

Lithuania has offered PSA testing to men aged 50 to 74 through a population-based programme since 2006; in its first ten years 70% of the men eligible were tested at least once.

Approvals

Lithuania is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Lithuania's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Lithuania, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Lithuania's own sources, beyond the programme records above.

Lithuania is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/lt.json; every country: /api/v1/countries.json.